7.02 USD
0 (0%)
Overall KMDA gets a fundamental rating of 6 out of 10. We evaluated KMDA against 529 industry peers in the Biotechnology industry. KMDA scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on KMDA. These ratings would make KMDA suitable for value investing!
1. Profitability
1.1 Basic Checks
KMDA had positive earnings in the past year.
KMDA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KMDA reported negative net income in multiple years.
Of the past 5 years KMDA 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.42%, KMDA belongs to the top of the industry, outperforming 91.71% of the companies in the same industry.
With an excellent Return On Equity value of 7.71%, KMDA belongs to the best of the industry, outperforming 91.53% of the companies in the same industry.
The Return On Invested Capital of KMDA (6.66%) is better than 92.66% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for KMDA is significantly below the industry average of 18.22%.
The 3 year average ROIC (2.98%) for KMDA is below the current ROIC(6.66%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.42% | ||
| ROE | 7.71% | ||
| ROIC | 6.66% |
ROA(3y)1.84%
ROA(5y)2.59%
ROE(3y)2.55%
ROE(5y)3.2%
ROIC(3y)2.98%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 11.70%, KMDA belongs to the top of the industry, outperforming 91.71% of the companies in the same industry.
In the last couple of years the Profit Margin of KMDA has declined.
With an excellent Operating Margin value of 15.88%, KMDA belongs to the best of the industry, outperforming 93.60% of the companies in the same industry.
KMDA's Operating Margin has declined in the last couple of years.
KMDA's Gross Margin of 43.75% is fine compared to the rest of the industry. KMDA outperforms 74.39% of its industry peers.
KMDA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.88% | ||
| PM (TTM) | 11.7% | ||
| GM | 43.75% |
OM growth 3YN/A
OM growth 5Y-7.02%
PM growth 3YN/A
PM growth 5Y-12.51%
GM growth 3Y14.12%
GM growth 5Y2.16%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KMDA is destroying value.
KMDA has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, KMDA has more shares outstanding
The debt/assets ratio for KMDA is higher compared to a year ago.
2.2 Solvency
KMDA has an Altman-Z score of 3.28. This indicates that KMDA is financially healthy and has little risk of bankruptcy at the moment.
KMDA has a Altman-Z score of 3.28. This is in the better half of the industry: KMDA outperforms 68.74% of its industry peers.
KMDA has a debt to FCF ratio of 0.63. This is a very positive value and a sign of high solvency as it would only need 0.63 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.63, KMDA belongs to the best of the industry, outperforming 94.73% of the companies in the same industry.
KMDA has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.04, KMDA is in line with its industry, outperforming 40.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | 0.63 | ||
| Altman-Z | 3.28 |
ROIC/WACC0.78
WACC8.52%
2.3 Liquidity
KMDA has a Current Ratio of 4.03. This indicates that KMDA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.03, KMDA perfoms like the industry average, outperforming 47.65% of the companies in the same industry.
KMDA has a Quick Ratio of 2.24. This indicates that KMDA is financially healthy and has no problem in meeting its short term obligations.
KMDA has a Quick ratio of 2.24. This is in the lower half of the industry: KMDA underperforms 72.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.03 | ||
| Quick Ratio | 2.24 |
3. Growth
3.1 Past
KMDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.57%, which is quite impressive.
The earnings per share for KMDA have been decreasing by -13.60% on average. This is quite bad
Looking at the last year, KMDA shows a quite strong growth in Revenue. The Revenue has grown by 10.36% in the last year.
KMDA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.82% yearly.
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5Y-13.6%
EPS Q2Q%28.57%
Revenue 1Y (TTM)10.36%
Revenue growth 3Y15.82%
Revenue growth 5Y4.82%
Sales Q2Q%12.63%
3.2 Future
KMDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.56% yearly.
KMDA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.40% yearly.
EPS Next Y41.23%
EPS Next 2Y28.87%
EPS Next 3Y26.56%
EPS Next 5YN/A
Revenue Next Year12.48%
Revenue Next 2Y11.19%
Revenue Next 3Y9.4%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.50 indicates a rather expensive valuation of KMDA.
Based on the Price/Earnings ratio, KMDA is valued cheaply inside the industry as 94.54% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of KMDA to the average of the S&P500 Index (26.56), we can say KMDA is valued slightly cheaper.
With a Price/Forward Earnings ratio of 16.26, KMDA is valued correctly.
Based on the Price/Forward Earnings ratio, KMDA is valued cheaply inside the industry as 96.05% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of KMDA to the average of the S&P500 Index (23.79), we can say KMDA is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.5 | ||
| Fwd PE | 16.26 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KMDA indicates a rather cheap valuation: KMDA is cheaper than 97.36% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, KMDA is valued cheaper than 94.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.09 | ||
| EV/EBITDA | 8.01 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KMDA may justify a higher PE ratio.
A more expensive valuation may be justified as KMDA's earnings are expected to grow with 26.56% in the coming years.
PEG (NY)0.47
PEG (5Y)N/A
EPS Next 2Y28.87%
EPS Next 3Y26.56%
5. Dividend
5.1 Amount
KMDA has a Yearly Dividend Yield of 2.85%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 1.15, KMDA pays a better dividend. On top of this KMDA pays more dividend than 98.68% of the companies listed in the same industry.
KMDA's Dividend Yield is rather good when compared to the S&P500 average which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.85% |
5.2 History
KMDA does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y28.87%
EPS Next 3Y26.56%
NASDAQ:KMDA (12/12/2025, 8:00:02 PM)
7.02
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners11.39%
Inst Owner Change3.21%
Ins Owners2.34%
Ins Owner ChangeN/A
Market Cap404.91M
Revenue(TTM)174.79M
Net Income(TTM)20.44M
Analysts84.44
Price Target15.05 (114.39%)
Short Float %0.1%
Short Ratio0.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.85% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.52%
Min EPS beat(2)-4.61%
Max EPS beat(2)45.66%
EPS beat(4)3
Avg EPS beat(4)17.85%
Min EPS beat(4)-4.61%
Max EPS beat(4)45.66%
EPS beat(8)6
Avg EPS beat(8)19.32%
EPS beat(12)9
Avg EPS beat(12)7.95%
EPS beat(16)10
Avg EPS beat(16)-82.64%
Revenue beat(2)1
Avg Revenue beat(2)-0.44%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)0.61%
Revenue beat(4)2
Avg Revenue beat(4)-0.44%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)2.19%
Revenue beat(8)3
Avg Revenue beat(8)-0.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)6
Avg Revenue beat(16)1.07%
PT rev (1m)-7.81%
PT rev (3m)-7.81%
EPS NQ rev (1m)-22.5%
EPS NQ rev (3m)-22.5%
EPS NY rev (1m)-5.88%
EPS NY rev (3m)2.86%
Revenue NQ rev (1m)-0.9%
Revenue NQ rev (3m)-0.9%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.5 | ||
| Fwd PE | 16.26 | ||
| P/S | 2.32 | ||
| P/FCF | 22.09 | ||
| P/OCF | 14.3 | ||
| P/B | 1.53 | ||
| P/tB | 1.72 | ||
| EV/EBITDA | 8.01 |
EPS(TTM)0.36
EY5.13%
EPS(NY)0.43
Fwd EY6.15%
FCF(TTM)0.32
FCFY4.53%
OCF(TTM)0.49
OCFY6.99%
SpS3.03
BVpS4.6
TBVpS4.07
PEG (NY)0.47
PEG (5Y)N/A
Graham Number6.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.42% | ||
| ROE | 7.71% | ||
| ROCE | 8.43% | ||
| ROIC | 6.66% | ||
| ROICexc | 8.52% | ||
| ROICexgc | 9.66% | ||
| OM | 15.88% | ||
| PM (TTM) | 11.7% | ||
| GM | 43.75% | ||
| FCFM | 10.49% |
ROA(3y)1.84%
ROA(5y)2.59%
ROE(3y)2.55%
ROE(5y)3.2%
ROIC(3y)2.98%
ROIC(5y)N/A
ROICexc(3y)3.78%
ROICexc(5y)N/A
ROICexgc(3y)8.93%
ROICexgc(5y)N/A
ROCE(3y)3.78%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-12.12%
ROICexc growth 3YN/A
ROICexc growth 5Y-24.72%
OM growth 3YN/A
OM growth 5Y-7.02%
PM growth 3YN/A
PM growth 5Y-12.51%
GM growth 3Y14.12%
GM growth 5Y2.16%
F-Score7
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | 0.63 | ||
| Debt/EBITDA | 0.22 | ||
| Cap/Depr | 65.68% | ||
| Cap/Sales | 5.72% | ||
| Interest Coverage | 35.82 | ||
| Cash Conversion | 65.9% | ||
| Profit Quality | 89.64% | ||
| Current Ratio | 4.03 | ||
| Quick Ratio | 2.24 | ||
| Altman-Z | 3.28 |
F-Score7
WACC8.52%
ROIC/WACC0.78
Cap/Depr(3y)51.63%
Cap/Depr(5y)66.68%
Cap/Sales(3y)4.57%
Cap/Sales(5y)4.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5Y-13.6%
EPS Q2Q%28.57%
EPS Next Y41.23%
EPS Next 2Y28.87%
EPS Next 3Y26.56%
EPS Next 5YN/A
Revenue 1Y (TTM)10.36%
Revenue growth 3Y15.82%
Revenue growth 5Y4.82%
Sales Q2Q%12.63%
Revenue Next Year12.48%
Revenue Next 2Y11.19%
Revenue Next 3Y9.4%
Revenue Next 5YN/A
EBIT growth 1Y56.4%
EBIT growth 3YN/A
EBIT growth 5Y-2.54%
EBIT Next Year134.37%
EBIT Next 3Y34.69%
EBIT Next 5YN/A
FCF growth 1Y918.17%
FCF growth 3YN/A
FCF growth 5Y7.84%
OCF growth 1Y325.9%
OCF growth 3YN/A
OCF growth 5Y11.54%
KAMADA LTD / KMDA FAQ
Can you provide the ChartMill fundamental rating for KAMADA LTD?
ChartMill assigns a fundamental rating of 6 / 10 to KMDA.
Can you provide the valuation status for KAMADA LTD?
ChartMill assigns a valuation rating of 8 / 10 to KAMADA LTD (KMDA). This can be considered as Undervalued.
Can you provide the profitability details for KAMADA LTD?
KAMADA LTD (KMDA) has a profitability rating of 7 / 10.
Can you provide the financial health for KMDA stock?
The financial health rating of KAMADA LTD (KMDA) is 6 / 10.
Can you provide the expected EPS growth for KMDA stock?
The Earnings per Share (EPS) of KAMADA LTD (KMDA) is expected to grow by 41.23% in the next year.